Marker Therapeutics, Inc.
MRKR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001094038
No open-market purchases or sales by Marker Therapeutics, Inc. insiders were filed in the last 90 days; 35 institutions reported holding it in 13F filings for Q2 2026, worth $5.84M in total; no superinvestor holds it.
Holders of 5% or more of MRKR
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Marker Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Blue Owl Capital Holdings LP | 13G/A | 9.99%1.13M shares | +4.81 ppfrom 5.18% | Feb 14, 20252 filings | May 15, 2025 | SEC |
| New Enterprise Associates 16, L.P. | 13D/A | 9.90%1.67M shares | −2.70 ppfrom 12.60% | Mar 26, 20214 filings | Nov 17, 2025 | SEC |
| Alyeska Investment Group, L.P. | 13G/A | 9.90%1.28M shares | −0.09 ppfrom 9.99% | Feb 14, 20252 filings | Nov 14, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
13 Schedule 13D and 13G filings on Marker Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Nov 17, 20254:22 PM ET | New Enterprise Associates 16, L.P.and 9 others | 13D/A | 9.90%1.67M shares | −2.70 ppfrom 12.60% | Nov 13, 2025 | SEC |
| Nov 14, 20258:08 PM ET | Alyeska Investment Group, L.P.and 2 others | 13G/A | 9.90%1.28M shares | −0.09 ppfrom 9.99% | Sep 30, 2025 | SEC |
| Aug 20, 20254:58 PM ET | Wilson John Robert | 13D/A | 4.96%641.8K shares | −0.14 ppfrom 5.10%Below 5% | Aug 19, 2025 | SEC |
| Aug 19, 20252:42 PM ET | Wilson John Robert | 13D/A | 5.10%659.9K shares | – | Aug 15, 2025 | SEC |
| Aug 18, 20255:34 PM ET | New Enterprise Associates 16, L.P.and 9 others | 13D/A | 12.60%1.63M shares | −2.60 ppfrom 15.20% | Aug 14, 2025 | SEC |
| May 15, 20254:13 PM ET | Blue Owl Capital Holdings LP | 13G/A | 9.99%1.13M shares | +4.81 ppfrom 5.18% | Mar 31, 2025 | SEC |
| Feb 14, 20255:09 PM ET | Blue Owl Capital Holdings LP | 13G | 5.18%554.3K shares | New | Dec 31, 2024 | SEC |
| Feb 14, 20254:26 PM ET | Alyeska Investment Group, L.P.and 2 others | 13G | 9.99%1.07M shares | New | Dec 31, 2024 | SEC |
| Dec 23, 20244:30 PM ET | New Enterprise Associates 16, L.P.and 9 others | 13D/A | 15.20%1.63M shares | – | Dec 19, 2024 | SEC |
| Mar 3, 2023 | Aisling Capital IV, LP | 13D/AOld format | – | – | – | SEC |
| Mar 26, 2021 | New Enterprise Associates 16, L.P. | 13D/AOld format | – | – | – | SEC |
| Mar 24, 2021 | Leen Ann M. | 13D/AOld format | – | – | – | SEC |
| Mar 15, 2021 | Eastern Capital LTD | 13D/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Marker Therapeutics, Inc. shares.
No Form 144 notices for Marker Therapeutics, Inc. are on file.